{"id":922736,"date":"2025-12-29T09:18:10","date_gmt":"2025-12-29T14:18:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/"},"modified":"2025-12-29T09:18:10","modified_gmt":"2025-12-29T14:18:10","slug":"longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/","title":{"rendered":"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <em>Mission-aligned community focused on accelerating breakthroughs in Alzheimer\u2019s disease, Parkinson\u2019s disease and related conditions<\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>Supported by Health Moonshot Champions, including the Alzheimer\u2019s Drug Discovery Foundation (ADDF) and Gates Ventures<\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>Apollo House, the Founders &amp; Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwide<\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>Longeveron will also be hosting meetings with institutional investors and potential partners during the week<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">MIAMI, Dec.  29, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3LTuUQFXOjlFBw4fdRG7dK0R3eOEd0oEdSDAbRki3dVLpVQOAZF_4l8G-ApUtFaURXxTUl5XyUqnob5Pgip3qlJHtTZXQ22IVJTpwsArQJY=\" rel=\"nofollow\" target=\"_blank\">Longeveron Inc.<\/a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that, as a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j8RY6aCfObxQj3IldJb7pbTB5383RBSNy8o829LDOVEpmQ9T5ESK2ZvXovi-Ex8Gqlnx1BKwAuwctiniC0ZsN0A3cUB5BuTfjYXf4iEW_HU=\" rel=\"nofollow\" target=\"_blank\">StartUp Health<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RC94fl936W4R_fQvpF8hKQlh371oKseL1zSyw7LrhbNaWgN-35oT32iAufvoB72X0p8WkYy3DqQ52M1_41Lrduj9pEA8al6gaekLsJBBR9WncH4wnotVgNXMV51lu9m3Orb5aKJcvQFhzMGdRsTCbBsO6ZhXJpERxqqS5ZITHokmGq2j3O2UOHBIbfLL07Rc\" rel=\"nofollow\" target=\"_blank\">Alzheimer\u2019s &amp; Brain Health Moonshot<\/a> company, it will be participating in StartUp Health <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DHpVYMeL6xOmGRduxZmovTnZ8HBjYgh152VDvhOucz0lr2QSRR71dfcNMlN0bkyRnpDzILr-czyAlN1wWXnGe4lPRmAMPwcMcZI53-bQCcNhZrPniNaPfNqX3S2pOVxI\" rel=\"nofollow\" target=\"_blank\">Apollo House<\/a> during JPM Healthcare Week in January 2026.<\/p>\n<p align=\"justify\">StartUp Health Alzheimer\u2019s &amp; Brain Moonshot is a mission-aligned community focused on accelerating breakthroughs in Alzheimer\u2019s disease, Parkinson\u2019s disease and related conditions, supported by Health Moonshot Champions, including the Alzheimer\u2019s Drug Discovery Foundation (ADDF) and Gates Ventures. Apollo House, the Founders &amp; Funders Networking Summit, is intended to bring together founders, funders and industry leaders addressing Health Moonshots worldwide.<\/p>\n<p align=\"justify\">Longeveron will also be hosting meetings with institutional investors and potential partners during JPM Healthcare Week. Please contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CBByxl0I7jRiTKvCOzi2eefIAnWoOyGtn0Ro4vJVscYwgpGqzQ0TSd5cGikdDuEY7cv6hBtI9pQ-Z1EMOtckNVw4fMfXZNRmJy0Add_4An4=\" rel=\"nofollow\" target=\"_blank\">info@longeveron.com<\/a> to schedule a meeting with members of Longeveron\u2019s senior management.<\/p>\n<p align=\"justify\">\n        <strong>About Longeveron Inc.<br \/><\/strong>Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s lead investigational product is laromestrocel (LOMECEL-B<sup>\u00ae<\/sup>), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer\u2019s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program &#8211; Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program &#8211; Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DyBlo1xK9fLEEoe2mpt-xJ7GnhIjMPFhdtDxaDS0lcfgK1Qe5FxdUcas9ShGjkctoSEuq1hGs-for5AqW2fwVD7dHWMPWO55Jy4WFMcogNksNJhbWbJMI6Zt-vri-I4rQxR_e4uL8kITYNQ5zNn7gQIYDwouOvef-4BntKlH29kL6CURD3TJTcOu3LRNvp7k46641t151EQdjLX0keLac73Yu5MHzbR77JD-c-uNdL91-hHbFijNevupBbUrSxzyvosJzsnbKAWpHsGSZi_dtA==\" rel=\"nofollow\" target=\"_blank\">www.longeveron.com<\/a>\u00a0or follow Longeveron on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8Tp6EDxIDAvTwQBA4TG8qwweDtBE0QvfESKYfXKEBnncxPhwDI2pq7pWwcdFBVx98Bj9P3MJOAOsFVAlIqgK3SKcQTsAsFSog0anucu8eIUmACMrPkuSKxiO5LfJeM5Me436EYFBrIR_evkF_XWgcaG7DxV7rgqQEd-tu7qDwHavWnTdEWF77DikLVWJ8y-ayXnpUCRrStMCGDMOOztWYXjJx9Pjq8h6hbOT1x3N1fOWuUOpnZxLow54TPa7tj2xYS1c246ZO6JBSrB-BQ-8DA==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yFSKYLsKHxdNRbGE7jtSAxyfCWgiwqBGc-BRP93N8R6DEIk0ccV1286DkWBxD8Gu48hgE-ZgcnYqKOG0aTGtiuXLpItvIqfFHJtIUw9vkbM7bx0ksrntCEVqNskYSDMZ0QQniaxd8CrppjLk2JZh7TVfDd6KfstxFDdpccIGcumPwmw9owWGxe8Y3PoVkMxpIeQP6h3u-aQsD1QStkSb1Q==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SBljrdDCCSVJhh95PJLSNKbDFY9s_xKvlyDFxFxOm0u-I_CdAB329Zn_vdHulwTFxYYUpzDrv15tdWVzvhwzxqlUETRhdkN8ypIFDHULGiuo5DUCi1mvexLloURVEugQtJHfF2gRxJZgyE64RDcwLs9IeJEcj-70YI6C5CDq1ACAP-dZpfJ4E5JwJ6fPt4ia8eZbIDRMw-7ASJ5TX-ugFTBPQorieg0WM0UMR6RNjUYXA8NPHBqK_ywWzPgKdxaO\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management\u2019s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpects,\u201d \u201cintend,\u201d \u201clooks to,\u201d \u201cmay,\u201d \u201con condition,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cpreliminary,\u201d \u201cproject,\u201d \u201csee,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.<\/p>\n<p align=\"justify\">Further information relating to factors that may impact the Company\u2019s results and forward-looking statements are disclosed in the Company\u2019s filings with the Securities and Exchange Commission, including Longeveron\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company\u2019s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Derek Cole<br \/>Investor Relations Advisory Solutions<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P0SNSGopZSVRXwvqo5y49ngtynUaNBVPLZsSolnNh7GuNt-HMGDgZ807IeusbvE9Qj2xLKjnaL15fLRxbHmRAx4iynG65A-YVo-nK-ejE-R1SoNBuL2zIDaHgZk5PT5J\" rel=\"nofollow\" target=\"_blank\">derek.cole@iradvisory.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTY3YzU1ZmUtMTZjZi00OGNhLWJkOTgtOWE3ZGIyZTBjODU5LTEyMTg2MTMtMjAyNS0xMi0yOS1lbg==\/tiny\/Longeveron.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mission-aligned community focused on accelerating breakthroughs in Alzheimer\u2019s disease, Parkinson\u2019s disease and related conditions Supported by Health Moonshot Champions, including the Alzheimer\u2019s Drug Discovery Foundation (ADDF) and Gates Ventures Apollo House, the Founders &amp; Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwide Longeveron will also be hosting meetings with institutional investors and potential partners during the week MIAMI, Dec. 29, 2025 (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that, as a StartUp HealthAlzheimer\u2019s &amp; Brain Health Moonshot company, it will be participating in StartUp Health Apollo House during JPM Healthcare Week in January 2026. StartUp &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-922736","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mission-aligned community focused on accelerating breakthroughs in Alzheimer\u2019s disease, Parkinson\u2019s disease and related conditions Supported by Health Moonshot Champions, including the Alzheimer\u2019s Drug Discovery Foundation (ADDF) and Gates Ventures Apollo House, the Founders &amp; Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwide Longeveron will also be hosting meetings with institutional investors and potential partners during the week MIAMI, Dec. 29, 2025 (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that, as a StartUp HealthAlzheimer\u2019s &amp; Brain Health Moonshot company, it will be participating in StartUp Health Apollo House during JPM Healthcare Week in January 2026. StartUp &hellip; Continue reading &quot;Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T14:18:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026\",\"datePublished\":\"2025-12-29T14:18:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/\"},\"wordCount\":1027,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/\",\"name\":\"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=\",\"datePublished\":\"2025-12-29T14:18:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/","og_locale":"en_US","og_type":"article","og_title":"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Market Newsdesk","og_description":"Mission-aligned community focused on accelerating breakthroughs in Alzheimer\u2019s disease, Parkinson\u2019s disease and related conditions Supported by Health Moonshot Champions, including the Alzheimer\u2019s Drug Discovery Foundation (ADDF) and Gates Ventures Apollo House, the Founders &amp; Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwide Longeveron will also be hosting meetings with institutional investors and potential partners during the week MIAMI, Dec. 29, 2025 (GLOBE NEWSWIRE) &#8212; Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that, as a StartUp HealthAlzheimer\u2019s &amp; Brain Health Moonshot company, it will be participating in StartUp Health Apollo House during JPM Healthcare Week in January 2026. StartUp &hellip; Continue reading \"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-29T14:18:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026","datePublished":"2025-12-29T14:18:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/"},"wordCount":1027,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/","name":"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=","datePublished":"2025-12-29T14:18:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzY5NCM3MzM4MDg5IzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-selected-as-a-startup-health-alzheimers-disease-moonshot-company-will-participate-in-startup-health-apollo-house-during-jpm-healthcare-week-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longeveron, Selected as a StartUp Health Alzheimer\u2019s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=922736"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922736\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=922736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=922736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=922736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}